Assay

Financial-condition grades for SEC filers

Company Report · as of Oct 9, 2026


HomeCompaniesSectorsCalendarLast night

Lantern Pharma Inc.LTRN · healthcare
GradeNonecomputable_factors_below_threshold: 5 of 14 inputs computable; 7 are required
Reliability0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025
Size bandunder $12.5M assetstotal assets $11.0M[1]
Warningsshort runway, thin data, distressnot computable: dilution, degenerate inputs, fortress balance sheet
Inputs computable5 of 14
Graded fromfilings received through Apr 30, 2026162 days before the rescan; every figure keyed to the SEC receipt date
Last close$0.842026-10-08; market equity $10.7M; iex feed
Price used in gradeNone
Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history
$2$4NovDecJanFebMarAprMayJunJulAugSepOct$0.83
ABCDE20132014201520162017201820192020202120222023202420252026

Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date.

Open this report as it stood on

Letter setLetterPercentileBand
Jan 21, 2012nonen/a
Mar 21, 2021nonen/aQ2
Apr 21, 2026nonen/aQ1

Each date opens the report as it stood on that rescan.

Business, in the company's words. Opening of Item 1 of the 10-K received Mar 30, 2026; the document on sec.gov.

are an artificial intelligence (A.I.) focused company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and development. Our development portfolio includes three clinical stage oncology focused product candidates and consists of small molecules that others have tried, but failed, to develop into an approved commercialized drug, as well as new compounds that we are developing with the assistance of our proprietary A.I. platform and our biomarker driven approach. Our A.I.

Warnings [top]

Short runway. cash runway is 5.7 months[2]
Thin data. 5 of 14 grade factors are computable; minimum is 7
Distress. CHS probability 14.353906%; universe top-decile threshold 1.068854%

7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.

The Fourteen Inputs [top]

Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.

InputPercentile, 0 to 100ValueSourcePeer medianPercentilePeersPeriod end
Profitability, sleeve percentile 49.8
Gross profitabilitynot computable32.2%
one or more required annual facts are missing
Return on invested capitalnot computable9.3%
one or more required annual facts are missing
Accruals ratio(7.9%)[1,3-5](6.6%)49.88112025-12-31
Gross margin stability, five yearsnot computable2.8 pts
five annual gross margins are required; found 0
Solvency, sleeve percentile 82.2
Twelve-month failure probability14.35%0.07%98.82482026-06-30
Altman Z double-prime(33.19)[1,6-11](0.31)82.47562025-12-31
Net debt to EBITDAnot computable1.82x
one or more required annual facts are missing
Interest coveragenot computable(4.51x)
one or more required annual facts are missing
Current ratio2.40x[6-7]2.96x65.48392025-12-31
Growth and financing, sleeve percentile 97.4
Revenue growth, three-year compoundnot computable10.0%
four annual observations are required; found 0
Free cash flow growth, three-year compoundnot computable10.9%
current FCF must be positive and base FCF must exceed $100,000
Reinvestment ratenot computable37.1%
one or more required annual facts are missing
Asset growth, three years(42.8%)[1,5,12-13]2.1%97.47042025-12-31
Net share issuance, one yearnot computable2.5%
prior share count is 47 days earlier

Gross profitability. Revenue less cost of goods sold, over total assets.

Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.

Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.

Twelve-month failure probability. CHS model; lower is stronger.

Net debt to EBITDA. Lower is stronger.

Net share issuance, one year. Split-adjusted; lower is stronger.

Among 371 Peers [top]

What the Price Implies [top]

Market measures at the 2026-10-08 close. None enters the grade. Percentile among graded peers with the same measure.

MeasureValuePeer medianPercentileReading
Twelve-month price change, skipping the latest month(53.3%)8.0%12hotter than 12 of 100 peers
Distance from 52-week high(82.0%)(31.4%)8closer to its high than 8 of 100 peers
EBIT to enterprise valuenot computable(1.5%)required accounting or market input is missing
Free cash flow yield(147.8%)(1.0%)4pricier than 96 of 100 peers
Book value to price(0.30)0.285pricier than 95 of 100 peers
Sales to pricenot computable0.31required accounting or market input is missing
Composite equity issuance, five years13.5%20.3%44more equity-funded than 44 of 100 peers
Relative strength against the sector, log excess return(0.97)(0.14)12ahead of 12 of 100 peers

Inputs: market equity $10.6M; EBIT -$18.0M; free cash flow -$15.7M; book equity -$3.2M; cash $6.7M[14].

Diagnostics [top]

Diagnostics do not feed the grade.

Piotroski F-score: None of 9, period end 2025-12-31
Return on assets above zero(66.9%)✗ fail[3,5]
Operating cash flow above zero-$15.7M✗ fail[4]
Return on assets improved(19.3 pts)✗ fail[3,5,12,15]
Operating cash flow exceeds net income$1.4M✓ pass[3-4]
Long-term leverage felln/a[1,5,12]
Current ratio improved(342.9 pts)✗ fail[6-7,16-17]
No new shares issuedn/a[18-19]
Gross margin improvedn/a
Asset turnover improvedn/a[5,12]
Cash, filings, liquidity
Cash and equivalents$6.7M[2]
Operating cash flow, four quarters-$14.1M[2,4,20-23]
Months of runway5.7
Late filings, two years0
NT 10-K or NT 10-Q
Days since last periodic filing56
10-Q received Aug 14, 2026
Median daily dollar volume$286,940
63 sessions
Days since newest grade input162

Downloads [top]

Sources [top]

Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.

#ConceptXBRL tagValuePeriod endReceivedFormLinks
1assetsus-gaap:Assets$11.0M2025-12-312026-03-3010-Kfiling · viewer · series
2cashus-gaap:CashAndCashEquivalentsAtCarryingValue$6.7M2026-06-302026-08-1410-Qfiling · viewer · series
3net incomeus-gaap:NetIncomeLoss-$17.1M2025-12-312026-03-3010-Kfiling · viewer · series
4operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$15.7M2025-12-312026-03-3010-Kfiling · viewer · series
5assetsus-gaap:Assets$25.6M2024-12-312026-03-3010-Kfiling · viewer · series
6current assetsus-gaap:AssetsCurrent$10.8M2025-12-312026-03-3010-Kfiling · viewer · series
7current liabilitiesus-gaap:LiabilitiesCurrent$4.5M2025-12-312026-03-3010-Kfiling · viewer · series
8retained earningsus-gaap:RetainedEarningsAccumulatedDeficit-$93.1M2025-12-312026-03-3010-Kfiling · viewer · series
9operating incomeus-gaap:OperatingIncomeLoss-$18.0M2025-12-312026-03-3010-Kfiling · viewer · series
10book equityus-gaap:StockholdersEquity$6.5M2025-12-312026-03-3010-Kfiling · viewer · series
11liabilitiesus-gaap:Liabilities$4.5M2025-12-312026-03-3010-Kfiling · viewer · series
12assetsus-gaap:Assets$43.6M2023-12-312025-03-2710-Kfiling · viewer · series
13assetsus-gaap:Assets$58.8M2022-12-312024-03-1810-Kfiling · viewer · series
14shares outstandingdei:EntityCommonStockSharesOutstanding12,784,1462026-08-102026-08-1410-Qfiling · viewer · series
15net incomeus-gaap:NetIncomeLoss-$20.8M2024-12-312026-03-3010-Kfiling · viewer · series
16current assetsus-gaap:AssetsCurrent$25.2M2024-12-312026-03-3010-Kfiling · viewer · series
17current liabilitiesus-gaap:LiabilitiesCurrent$4.3M2024-12-312026-03-3010-Kfiling · viewer · series
18shares outstandingdei:EntityCommonStockSharesOutstanding11,304,6972026-04-292026-04-3010-K/Afiling · viewer · series
19shares outstandingdei:EntityCommonStockSharesOutstanding11,254,6972026-03-132026-03-3010-Kfiling · viewer · series
20operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$6.7M2026-06-302026-08-1410-Qfiling · viewer · series
21operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$3.8M2026-03-312026-05-1510-Qfiling · viewer · series
22operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$12.9M2025-09-302025-11-1210-Qfiling · viewer · series
23operating cash flowus-gaap:NetCashProvidedByUsedInOperatingActivities-$8.3M2025-06-302026-08-1410-Qfiling · viewer · series

Limitations [top]

Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.

Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.

Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.

Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.

Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.